Pablo Legorreta is the Chief Executive Officer and Chairman of Royalty Pharma since its founding. He has a strong background in finance and holds an MBA from Columbia Business School. Before starting Royalty Pharma, he worked as an investment banker...

Pablo Legorreta is the Chief Executive Officer and Chairman of Royalty Pharma since its founding. He has a strong background in finance and holds an MBA from Columbia Business School. Before starting Royalty Pharma, he worked as an investment banker at Lazard Frères in major cities like Paris and New York. Under his leadership, Royalty Pharma has become a key player in the biopharmaceutical industry, acquiring royalties that help fund innovative treatments. Legorreta leads with a focus on aligning the company’s interests with the shareholders’ goals. Interestingly, his compensation comes mostly from profits of the manager and not from a traditional salary or bonuses. This shows a significant alignment with the company's performance. His holdings in Class A shares are impressive, reflecting his confidence in the long-term success of Royalty Pharma. Outside of work, he is also involved with non-profits aimed at improving healthcare education in Latin America, demonstrating his commitment to giving back. Additionally, he serves on several boards, contributing his expertise to multiple organizations. Notably, Pablo was born in April 1963 and is currently 60 years old, bringing a wealth of experience to his role.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

R

Pablo Legorreta

Founder and CEO of Royalty Pharma

Education

MBA from Columbia Business School

Field of Expertise

Finance & Banking - Finance

Sector of Economy

Healthcare

Born

April 1, 1963 - 62 years ago

CEO of Royalty Pharma for

4 years 10 months (Jun 2020 - Present)

Previous Experience

Founder of Royalty Pharma

Rivals

Competitors/colleagues of Pablo Legorreta

Holdings

See how much did Pablo Legorreta make over time.

Pablo Legorreta's financial journey with Royalty Pharma reflects significant movements in his holdings over time. Initially, his wealth surged in late 2022, peaking at around $144.57 million in December. However, this dipped in subsequent months, hitting $102.05 million by October...

Pablo Legorreta's financial journey with Royalty Pharma reflects significant movements in his holdings over time. Initially, his wealth surged in late 2022, peaking at around $144.57 million in December. However, this dipped in subsequent months, hitting $102.05 million by October 2023. As of now, he holds approximately $3.16 million in Class A shares, which shows a strong personal investment in the company. His wealth tied to his stock holdings represents a significant portion of his overall compensation and reflects his belief in the company's future. This aligns his success closely with that of Royalty Pharma, showcasing a commitment to driving company growth while managing risks associated with market fluctuations. His shares remain closely tied to the company's performance, emphasizing a robust connection between management and shareholder interests.

Insider Trading

See recent insider trades of Pablo Legorreta.

RPRX

$3.84M

RPRX at $29.51/share

Jun 28, 2023

Purchase

RPRX

$2.96M

RPRX at $32.89/share

Jun 12, 2023

Purchase

RPRX

$4.84M

RPRX at $32.25/share

May 24, 2023

Purchase

RPRX

$7.65M

RPRX at $33.25/share

May 16, 2023

Purchase

RPRX

292,190.49 shares

RPRX

Dec 30, 2022

Charity

RPRX

$560.00K

RPRX at $28.00/share

Jun 15, 2020

Purchase

Compensation History

See how much did Pablo Legorreta make over time.

In 2023, Pablo Legorreta's total compensation was reported at approximately $84.84 million, which reflects profits from his role at the Manager rather than a salary or cash bonuses. This unique structure means he does not receive traditional payouts for his executive role, but instead, earns a share of the overall profits generated by Royalty Pharma. He was not granted stocks or options, aligning his financial success directly with the company's performance. In previous years, his compensation fluctuated significantly, indicating his reliance on the success of Royalty Pharma's royalty acquisition strategy. The focus on long-term performance and shareholder alignment makes his compensation strategy distinct in the corporate landscape.

Year

2023

Total Compensation

$84.84M

Salary

$0.00

Board Justification

The compensation philosophy emphasizes alignment with shareholder interests and long-term performance, with a focus on attracting and retaining top talent through performance-based compensation.

Bonus

$0.00

Board Justification

Mr. Legorreta does not participate in our annual cash bonus plan.

Other

$84.84M

Board Justification

Mr. Legorreta is entitled to certain profits of the Manager, which consist of the management fee from Royalty Pharma less the expenses of the Manager, including operating expenses and the compensation of the employees of the Manager.

Restricted Stock

$0.00(0 Equity Performance Awards)

Board Justification

Mr. Legorreta is entitled to Equity Performance Awards but does not receive employee compensation for his services.

Performance Metrics

The performance metrics for Mr. Legorreta's compensation are tied to the profits of the Manager and the overall performance of Royalty Pharma.